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ABSTRACT
Objective To determine the safety and effi cacy of 
allogeneic mesenchymal stem cell transplantation 
(MSCT) in refractory systemic lupus erythematosus (SLE).
Methods A total of 15 patients with persistently 
active SLE underwent MSCT. Outcome was evaluated 
by changes in the SLE disease activity index (SLEDAI), 
serological features (anti-nuclear antibodies and anti-
double-stranded DNA (anti-dsDNA)), renal function and 
percentage of peripheral blood regulatory T cells.
Results From 11 March 2007 to 4 November 2008, 
15 patients with persistently active SLE were enrolled 
and underwent MSCT. The mean follow-up period was 
17.2±9.5 months. A total of 13 patients have been 
followed for more than 12 months. All patients clinically 
improved following treatment with mesenchymal stem 
cells with a marked decrease in the SLEDAI score and 
24 h proteinuria. At 12-month follow-up, SLEDAI scores 
decreased from 12.2±3.3 to 3.2±2.8 and proteinuria 
decreased from 2505.0±1323.9 to 858.0±800.7 
mg/24 h (all p<0.05, by paired t test, n=12). At 1-year 
follow-up in 13 patients, 2 had a relapse of proteinuria, 
while the other 11 continue to have decreased disease 
activity on minimal treatment. Anti-dsDNA levels 
decreased. Improvement in glomerular fi ltration rate 
was noted in two patients in which formal testing 
was performed. Non-renal-related manifestations also 
improved signifi cantly. No serious adverse events were 
reported.
Conclusion Allogeneic MSCT in patients with refractory 
lupus resulted in amelioration of disease activity, 
improvement in serological markers and stabilisation of 
renal function. MSCT appears benefi cial in treatment of 
patients with SLE refractory to conventional treatment 
options.
INTRODUCTION
Systemic lupus erythematosus (SLE) is an auto-
immune infl ammatory disease with multiorgan 
involvement including the kidney, brain, lung and 
haematopoietic systems. Lupus nephritis (LN) 
is a common major organ manifestation and is a 
signifi cant cause of morbidity and mortality. The 
most widely and classically used immunosup-
pressive therapies, notably corticosteroids and 
cyclophosphamide (CYC), have led to a signifi cant 
improvement in survival over the last few decades 
and decreased the progression to end-stage multio-
rgan failure. Both agents, however, are associated 
with signifi cant side effects including increased 
susceptibility to infection. Other immunosup-
pressants, such as mycophenolate mofetil (MMF) 
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and rituximab, appear to be effective in resistant 
SLE, but the cost is high and they also have signifi -
cant side effects.1–4 Even with use of these potent 
immunosuppressive regimens, some patients are 
refractory with progressive organ-damaging and 
life-threatening disease, including LN. Currently, 
haematopoietic stem cell (HSC) transplantation is 
used in some cases of refractory SLE, which results 
in disease improvement in most cases,5 6 but also 
causes signifi cant morbidity and mortality. The 
most common complications, including mucositis, 
transplantation-related infection and lung injury, 
have led to concerns regarding widespread use of 
this procedure in lupus. Given these current treat-
ment limitations, new therapies are needed with 
enhanced effi cacy and less toxicity than current 
treatment standards.
Mesenchymal stem cells (MSCs) are multipoten-
tial non-haematopoietic progenitor cells capable of 
differentiating into multiple cell lineages including 
osteoblasts, chondrocytes, myoblasts, adipocytes, 
endothelial cells, neuron-like cells, cardiomyocytes 
and hepatocytes.7–11 Because of their low immuno-
genicity due to their lacking expression of costimu-
latory molecules, they are able to escape alloantigen 
recognition. In addition, MSCs can inhibit immune 
responses in vitro and in vivo in a dose-dependent, 
non-human leucocyte antigen (HLA)-restricted 
manner.12 13 Their immune modulatory effect is 
related to effects on dendritic cell, T cell and natu-
ral killer cell development and activation.14–16 In 
human cell cultures, the magnitude of suppression 
is not reduced when the MSCs are separated from 
the lymphocytes in transwell plates, indicating that 
cell–cell contact is not required. These properties 
make MSCs promising candidate cells for prevent-
ing rejection in organ transplantation and treatment 
of autoimmune disease.
Over 10 years ago, Ikehara clarifi ed the dif-
ferences between normal and abnormal HSCs 
concluding that autoimmune diseases are ‘stem 
cell disorders’.17 Recently, we showed functional 
abnormalities exist in bone marrow-derived MSCs 
(BM-MSCs) from patients with SLE and MRL/
lpr mice.18 19 MSCs from patients with SLE grew 
more slowly than those of normal controls, aged 
more quickly and lost vitality sooner during pas-
sage. Moreover, MSCs from patients with lupus 
compared to controls were defective in secret-
ing cytokines (ie, transforming growth factor β) 
accompanied by downregulation of interleukin 6 
(IL-6) and IL-7 mRNA expression. A recent article 
also confi rmed defective phenotype, growth and 
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immunomodulatory effects of MSCs from patients with SLE 
compared with those from age-matched and sex-matched 
healthy donors.20
We therefore hypothesised that SLE is potentially a MSC-
mediated disease. If this hypothesis is true, then allogenic rather 
than autologous BM-MSCs transplantation should be an effec-
tive treatment for patients with lupus. The study of Carrion 
et al21 showed that autologous MSCs treatment did not improve 
disease activity in two patients with SLE, consistent with our 
hypothesis. Many preclinical assessments were performed to 
investigate potential therapeutic effects and possible mecha-
nisms of human bone marrow MSC transplantation (MSCT) 
on ameliorating autoimmune progression in MRL/lpr mice.19 22 
Human MSC from healthy donors reduced the proliferation of 
T lymphocytes in vitro from MRL/lpr mice in a dose-dependent 
fashion. At 2 weeks after transplantation with allogenic MSCs, 
we detected signifi cantly reduced serum levels of anti-double-
stranded DNA (anti-dsDNA) antibodies and 24 h proteinuria in 
MRL/lpr mice compared with control groups. Moreover, fl ow 
cytometric analysis showed that MSCT decreased the total 
number of CD4 T cells while increasing the T helper (Th) 1 cell 
subpopulation when compared with controls. Histopathological 
examination showed signifi cantly decreased renal pathol-
ogy in MSC-treated mice. Immunohistochemical studies fur-
ther revealed less expression of C3 in renal tissue after MSCT. 
Observations in animal models do not necessarily translate to 
humans. Therefore, this study was undertaken to determine 
whether MSCT can modulate the human immune system 
resulting in clinical improvement in patients with SLE refractory 
to current standards of treatment. Herein, we report short-term 
outcomes of 15 standard treatment refractory patients with SLE 
receiving MSCT in an unblinded clinical trial.
METHODS
Patient eligibility
From 11 March 2007 to 4 November 2008, 15 patients 
(14 women, 1 man) with SLE refractory to standard therapies 
were enrolled in an MSCT trial, which was approved by the 
Ethics Committee at Drum Tower Hospital and registered at 
http://ClinicalTrials.gov (identifier: NCT00698191). Informed 
consent was obtained from each patient and donor. All enrolled 
patients had at least 4 of 11 American College of Rheumatology 
criteria for SLE. Patient eligibility criteria also included one 
of the following features: (1) progressive and active disease 
with a Safety of Estrogens in Lupus Erythematosus: National 
Assessment (SELENA) SLE disease activity index (SLEDAI) score 
≥8, despite continuous treatment with intravenous pulse CYC 
with a total dosage of 400–800 mg every month for at least 6 
months or oral MMF 1000–2000 mg/day for at least 3 months 
and continued daily dosage of more than 20 mg of prednisone 
or its equivalent; (2) refractory immune-mediated thrombocyto-
poenia; (3) refractory LN. Refractory LN was defi ned either as 
proteinuria ≥1000 mg/24 h, serum creatinine (Cr) ≥1.5 mg / dl or 
decreased Cr clearance without end-stage renal failure in patients 
with WHO class IV/V glomerulonephritis despite 6 months of 
CYC or MMF.
MSC culturing and transplanting
The source of MSCs was BM-MSCs. Healthy donors between 
the ages of 18 and 40 years, who had no history of any signifi cant 
illness and had no physical or mental disability, were selected 
from members of the patient’s families without HLA matching, 
and all gave written informed consent. BM-MSCs were isolated 
by density gradient centrifugation and adherence methods as 
described previously with slight modifi cation.16 Briefl y, mononu-
clear cells were collected by gradient centrifugation and seeded 
at a density of 1×106 cells/cm2 in growth medium containing 
Dulbecco’s modifi ed Eagle medium, low glucose (DMEM-LG; 
Gibco) and 10% fetal bovine serum (FBS) (HyClone) (BM-GM). 
After 3 days of culture, non-adherent cells were removed and 
the medium was changed twice weekly thereafter. Once 60% 
to 80% confl uence was reached, adherent cells were replated at 
a density of 104 cells/cm2 in BM-GM for expansion. After two 
passages, the cells were harvested. Flow cytometric analysis 
confi rmed the cells expressed CD106, CD105, CD90, CD71, 
CD44, CD29, but not CD34, CD14, CD3 or CD45 (see supple-
mentary material). The capacity of MSCs to differentiate along 
adipogenic and osteogenic lineages was evaluated as described 
previously.7 Rigorous purifi cation and quality control were per-
formed to ensure MSCs purity. In most experiments, analyses 
indicated >95% purity (see supplementary material). Stem cells 
were used between passages 3 and 5. All the patients received 
one intravenous infusion of 1×106 cells/kg of body.
Maintenance treatment
All patients continued treatment with steroids at the time of 
infusion, with a taper of 5–10 mg every 2 weeks. Maintenance 
treatment 1 month after the MSCT included prednisone at 
5–10 mg/day and CYC 0.4–0.6 g per 2–3 months (see sup-
plementary material). As per the protocol, no other immu-
nosuppressive medications were used to avoid treatment 
confounders affecting the outcomes of MSCT, unless disease 
relapsed. If the patient’s status continued to improve, a with-
drawal schedule was followed to taper off prednisone. All 
modifi cations of treatment were with the agreement of the 
treating rheumatologist.
Assessment of disease status
After MSCT, each patient returned for follow-up at 1 week, 1, 3, 
6, 12 and 18 months and then once every half a year thereafter. 
Evaluations performed at these times included a physical exami-
nation, serological testing, urinary protein excretion, measures 
of regulatory T cells (Tregs) and assessment of glomerular fi ltra-
tion rate (GFR) (if results were previously abnormal). A SLEDAI 
score was assigned at each baseline and follow-up visit for each 
patient. If a patient was not able to return for follow-up, medical 
records and laboratory measures were collected from their local 
doctor or medical facility.
Laboratory tests
Serum levels of anti-nuclear antibodies (ANAs) and anti-dsDNA 
antibodies were determined by indirect immunofl uorescence 
using kits purchased from Euroimmun (Lübeck, Germany). The 
percentage of peripheral blood Tregs was analysed by fl ow cytom-
etry (Becton Dickinson, San Jose, California, USA). Monoclonal 
antibodies directed against CD4 and Foxp3 were purchased from 
eBioscience. Flow data were analysed with CellQuest software 
(Becton Dickinson). GFR was determined by the method of 
Tc-99m diethylenetriamine penta-acetic acid (DTPA) renography.
Statistical analysis
The paired or unpaired t test was used for statistical compari-
son of before and after MSCT variables (SLEDAI, ANA, anti-ds-
DNA, 24 h proteinuria and Tregs) by GraphPad Prism 4 software 
(V.4.03; GraphPad, La Jolla, California, USA). A level of p<0.05 
was considered statistically signifi cant.
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Non-LN-related manifestations
Of 11 patients with a long history of fatigue and/or loss of weight 
and/or low grade fever, 8 became free from these manifestations 
based on patient reporting at 3 months after MSCT. All eight 
patients had a signifi cant decrease in SLEDAI score compared 
with that of the baseline. Before transplantation, eight patients 
had skin rashes: four of them (cases 2, 4, 5 and 15), with severe 
cutaneous lesions healed completely at 1-month follow-up 
accompanied with decreased SLEDAI values, the other four 
(cases 3, 7, 8 and 12) responded at least partially and the lesions 
gradually faded at 3-month follow-up. One patient (case 10) had 
widespread skin ulcers due to herpes zoster. At 1 week after 
MSCT, the skin ulcers scabbed and the area involved reduced. 
Her lesions continued to heal 1 month after MSCT, paralleled 
with decreasing serum Cr, blood urea nitrogen and proteinuria. 
Complete blood count at 1-month follow-up showed normal 
white cell count (4.7×109 cells/litre), haemoglobin 10.5 g/dl and 
an improved platelet count (95×109 cells/litre).
Four out of six patients with involvement of the musculosk-
eletal system responded with decreased arthritis 1 month after 
MSCT. Serositis in two patients (ascites in cases 3 and 11) disap-
peared 1 week after MSCT. A total of 10 patients with refractory 
cytopoenia before enrolment all entered remission at 3-month 
follow-up. One patient with neurological system involvement 
(seizures and intractable headaches in case 2) had no seizures or 
headaches during follow-up after MSCT. Refractory hyperten-
sion in fi ve patients was controlled satisfactorily after the trans-
plantation accompanied with the amelioration of renal function 
abnormalities.
Toxicities
No serious adverse events were observed during or immediately 
after infusions of MSCs in any of the 15 patients with SLE. None 
of the patients developed graft versus host disease (GVHD) dur-
ing follow-up. The most common adverse event noted was upper 
respiratory tract infections reported by some of the patients dur-
ing follow-up visits. These mild infections were not thought to 
be related to the transplantation procedure. No serious infec-
tions occurred. None of the donors had any adverse events.
Regulatory T cell measure
To investigate the role of MSCT in Treg regulation, the percent-
ages of CD4 Foxp3+ cells among peripheral blood mononuclear 
cells were detected by fl ow cytometric analysis (fi gure 5) (see 
supplementary material). The percentage of CD4 Foxp3+ at 1 
week after MSCT increased to 4.58±0.51 vs 2.56±0.37 at base-
line (n=13, p<0.05). The percentages of Tregs cells at 3 and 6 
months were 4.80±0.77 (n=9) and 5.67±0.65 (n=6), respectively, 
both signifi cantly increased compared to the baseline level. 
CD4 Foxp3+ cells at 1 month were increased to 3.27±0.40 vs 
2.34±0.43 at baseline (n=9), but this change did not reach statis-
tical signifi cance (p=0.19).
DISCUSSION
MSCs mediate immune responses in vitro and in vivo, in addi-
tion to being multipotential, easy to isolate and culture and pos-
sessing high expansion potential. Interest is growing in the role 
and therapeutic application of MSCs in GVHD and autoimmune 
diseases. Trials exploring MSCT in the treatment of steroid-
 resistant, severe, acute GVHD achieved promising results.23 Our 
preclinical fi ndings from experimental animals showed MSCT 
was effective in inhibiting disease progression in MLR-lpr mice. 
The 24-h proteinuria, serum Cr, anti-dsDNA antibodies and 
RESULTS
Patient profi les
A total of 15 patients (14 women, 1 man) underwent allogeneic 
MSCT for refractory SLE. Their average age was 28.3 years 
(range 12–44). All had fulfi lled eligibility criteria for MSCT. The 
average disease duration was 91.1 months. All patients had 
proteinuria. Table 1 displays patient demographics and drug 
regimens received at the time of MSCT. Table 2 shows clinical 
symptoms of the 15 patients at the time of MSCT.
Assessment of disease activity
The mean follow-up period was 17.2±9.5 months (range 
3–36). In all, 13 patients were followed up for more than 12 
months, including 1 for 36 months, 1 for 30 months, 4 for 24 
months, 2 for 15 months and 5 for 12 months. Scores on the 
SLEDAI, a validated instrument of disease activity, improved 
signifi cantly at 12-month follow-up (12.1±3.3 vs 3.2±2.8 at 
baseline, n=12, p<0.05) (fi gure 1). The SLEDAI score remained 
<8 in 12 of 13 patients at 12-month follow-up. Four patients 
(cases 1, 5, 8 and 10) showed remarkable improvement with 
SLEDAI scores of 0 at 12-month follow-up. Sustained clinical 
remission has lasted for another 24 months in one of these 
four patients (case 1). Two patients (cases 2 and 12) had a 
fl are of disease with SLEDAI scores of 8 at their 24-month 
and 6-month follow-up, respectively (detailed data are shown 
in supplementary material). Of 15 patients, 1 (case 10) had 
discontinued all the other immunosuppressants with a grad-
ual taper of prednisone dosage after MSCT. She had SLEDAI 
score of 2 with a regimen of prednisone 10 mg/day at 3-month 
follow-up and had SLEDAI score of 0 with prednisone 5 mg/day 
at 12-month follow-up.
Serological fi ndings
ANA and anti-dsDNA antibodies decreased after MSCT. Lower 
serum titres of anti-dsDNA (11 of 15 patients) became signifi -
cant from baseline at 1 month (p<0.05) and 3 months (p<0.05) 
post transplant (fi gure 2). ANA antibodies also improved in par-
allel with anti-dsDNA, with the titre falling in nine patients at 
1 month and in eight patients at 3-month follow-up (fi gure 3), 
although these changes were not statistically different from 
baseline.
Renal function
Renal disease was assessed by urinary protein excretion and 
GFR. Reduced 24 h proteinuria was seen in all patients after 
MSCT (fi gure 4) (see supplementary material). Post-MSCT 
proteinuria signifi cantly decreased at 1 week (1430.7± 306.3 
vs 2538.0±382.3 mg at baseline, n=12, p<0.01), at 1 month 
(1385.8±273.6 vs 2540.8± 340.1 mg at baseline, n=13, p<0.01), 
at 3 months (1273.8±194.0 vs 2529.1± 492.0 mg at baseline, 
n=9, p<0.05), at 6 months (850.1±775.4 vs 2655.2± 1226.7 mg at 
baseline, n=12, p<0.01), at 12 months (858.0±800.7 vs 2505.0± 
1323.9 mg at baseline, n=12, p<0.01). GFR improved signifi -
cantly in two patients with low GFR on study entry. In case 1, 
the GFR at 18 months was 47 and 46 ml/min in the left and right 
kidneys, respectively, compared to 33 and 32 ml/min, respec-
tively, before MSCT. In case 10, the GFR at 6 months was 53 
and 45 ml/min the left and right kidneys, respectively, compared 
to 27 and 21 ml/min, respectively before MSCT. Four subjects 
(cases 2, 9, 10 and 14) experienced signifi cant improvement in 
their serum Cr levels: from 1.73 to 0.78 at 1-month follow-up, 
from 5.36 to 2.41 at 3 months, from 4.40 to 2.08 at 1 month and 
from 2.55 to 0.90 mg/dl at 3 months, respectively.
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Table 2 Clinical symptoms and manifestations at the time of MSCT
Symptoms and manifestations No. of patients
Fatigue, loss of weight, low grade fever 11
Skin rash, Raynaud’s phenomenon, alopecia 8
Arthritis, arthralgia, muscle pain, weakness 6
Serositis 2
Anaemia, leucocytopoenia, thrombocytopoenia 10
Lupus encephalopathy 1
Refractory hypertension 5
Proteinuria 15
MSCT, mesenchymal stem cell transplantation.
Figure 1 Systemic lupus erythematosus disease activity index 
(SLEDAI) scores in 15 patients with refractory systemic lupus 
erythematosus before and after mesenchymal stem cells transplantation. 
The SLEDAI score in all patients decreased after transplantation. 
The differences were signifi cant on follow-up at 1, 3, 6, 12 and 24 
months compared to the original indexes at the time of transplantation 
(all p<0.05, by paired t test for groups). Score was 0 at the time of 
transplantation.
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Figure 3 Anti-nuclear antibody (ANA) titres at the time of entry into 
the study and during the follow-up period in 15 patients with refractory 
systemic lupus erythematosus. Titres of ANA improved at 1-month and 
3-month follow-up.
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Figure 4 Results for 24-h proteinuria in 15 patients with refractory 
systemic lupus erythematosus before and after mesenchymal stem 
cells transplantation (MSCT). Reduced proteinuria was commonly seen 
during the follow-up period after MSCT at 1, 3, 6, 12 and 24 months (all 
p<0.05).
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Figure 5 The percentage of regulatory T cells (Tregs) in 15 patients 
with refractory systemic lupus erythematosus before and after 
mesenchymal stem cells transplantation (MSCT). The percentage 
of Tregs signifi  cantly increased at 1 week, 3 months and 6 months 
following MSCT (p<0.05).
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Figure 2 Anti-double-stranded DNA (dsDNA) antibody titres at 
the time of entry into the study and during the follow-up period in 15 
patients with refractory systemic lupus erythematosus. Differences from 
baseline were signifi cant at 1 and 3 months (p<0.05).
Th2 subpopulations all decreased after MSCT. Data presented 
herein indicate that 15 patients with refractory SLE had reduced 
disease activity following treatment with MSCT. In these 15 
patients, prednisolone was tapered stepwise successfully. At 
this time, a total of 13 patients were followed for more than 12 
months, with the 24 h proteinuria excretion decreased signifi -
cantly in 7 patients and normalised in 5 patients. Four patients 
showed remarkable improvement with SLEDAI scores of 0 at 
12-month follow-up. Sustained clinical remission has lasted for 
another 24 months in one of these four patients. A total of six 
patients were followed for more than 24 months, with the 24 h 
proteinuria excretion declined signifi cantly in one patient and 
normalised in three patients. One patient had discontinued all 
the other immunosuppressants with a gradually taper of predni-
sone dosage after MSCT and had a SLEDAI score of 0 with pred-
nisone 5 mg/day at 12-month follow-up. No patients had any 
serious adverse events either during or after infusion. In view 
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of the lessened doses of prednisolone and immunosuppressants 
in all patients after the MSCT, we believe that it was the MSCT 
that was the causative factor in the potent therapeutic effect, not 
ongoing CYC or corticosteroids.
At present, little is known about mechanisms by which 
allogeneic MSCT might improve lupus. We hypothesise the 
disease modulation is induced by several mechanisms. First, 
MSCs work as immunomodulators by producing soluble fac-
tors induced upon stimulation. Imbalance of cytokine homeo-
stasis is a prominent feature of experimental and human SLE. 
Many studies revealed increased levels of Th2 cytokines in 
murine lupus-prone strains as well as in patients with SLE.24–27 
Soluble Th1 and Th2 cytokines were measured by ELISA in 
serum of patients with SLE prior to and after transplantation 
(data not shown). We found a trend towards increased levels of 
interferon γ and tumour necrosis factor α suggesting a polari-
sation toward a Th1 phenotype in the Th1/Th2 balance after 
MSCT.
Second, MSCT may be associated with expansion of Tregs, 
which suppress the activity of autoreactive T cells and play a piv-
otal role in the maintenance of self-tolerance.28 The pathogen-
esis of SLE may be associated with a defect in the homeostatic 
control of different Tregs subsets.29 30 The frequency and func-
tion of Tregs was signifi cantly defi cient in patients with active 
SLE.31 32 At the same time, Foxp3 is described as the master con-
trolling gene for the development and function of Tregs.33 To 
date, Foxp3 remains the best marker for analysis and quantifi ca-
tion of Tregs population and has been reported to correlate with 
the function of Tregs. The mRNA level and protein expression 
of Foxp3 decreased in patients with new-onset active lupus.34 
Accordingly, Foxp3+ CD4 Tregs were assessed in the peripheral 
blood of patients prior to and after transplantation. The percent-
age of Treg cells increased signifi cantly at 1 week, 3 months and 
6 months after MSCT. We speculate that the augmentation of 
Tregs may be one of the vital mechanisms for the therapeutic 
effect of MSCs.
The third presumed mechanism of effect in lupus is based 
on the multipotentiality of MSCs. Many studies showed that 
human BM-MSCs are capable of differentiating into endothe-
lial cells in vitro.35 In addition, patients with SLE have increased 
levels of endothelial cell apoptosis by serum IgG.36 The patho-
logical changes in the endothelial cells are believed to be one of 
the factors initiating nephron damage in LN.37 38 We hypoth-
esise that, to some extent, differentiation of MSCs to endothe-
lial cells reconstructs the structure of the nephron and improves 
renal function. Presently no data exist that confi rm or refute this 
hypothesis.
In summary, this uncontrolled study showed effi cacy of 
MSCT in 15 patients with refractory SLE, albeit with a short 
follow-up length. Randomised clinical studies are needed to 
compare MSCT with more conventional approaches. Once effi -
cacy is confi rmed, further clinical trials are needed to standardise 
study entry criteria, clinical response criteria, post-transplant 
immunosuppression schedule and treatment of relapses.
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